Tango Therapeutics, Inc.

This study tests a new drug called TNG260 combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific gene change (STK11 mutation). The goal is to find the safest dose and see if the combination can shrink tumors. About 126 adults with…

This study tests a new oral drug, TNG456, in people with advanced solid tumors that lack a gene called MTAP. The drug aims to slow or stop cancer growth by blocking a protein these tumors rely on. The trial has two parts: first finding the safest dose, then testing how well it wo…

This study tests a new oral drug, TNG462, in people with advanced solid tumors that have a specific genetic deletion (MTAP). The goal is to find the safest dose and see if the drug can shrink or slow tumor growth, either alone or with another drug. About 225 adults with various c…

This study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …